Skip to main content

Table 1 Reagents and results in immunohistochemistry.

From: Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report

Antigens

Antibodies (clone)

Sources

Giant cell sarcomatoid

SCC

TCC

Pancytokeratin

AE1/3

Dako Corp. Glostrup, Denmark

++

+++

+++

Pancytokeratin

CAM5.2

Becton Dickinson Co. CA, USA

++

+++

+++

HMWCK

34βE12

Dako

+

+

++

CK5/6

D5/16

Dako

+

++

++

CK7

N1626

Dako

+

+

++

CK8

35βH11

Dako

+

++

++

CK14

LL002

Novocastra, Newcastle upon type, UK

+

+

++

CK 18

DC10

Dako

++

+++

+++

CK 19

RCK 108

Progen, Heidelberg, Germany

-

+

+

CK20

K20.8

Dako

-

-

++

EMA

E29

Dako

+

+

++

Chromogranin

DAK-A3

Dako

-

-

-

Synaptophysin

Polyconal

Dako

-

-

-

CD56

MOC-1

Dako

-

-

-

CD68

KP-1

Dako

-

-

-

Melanosome

HMB45

Dako

-

-

-

Vimentin

Vim 3B4

Dako

+++

-

-

Desmin

D33

Dako

-

-

-

S100 protein

polyclonal

Dako

-

-

-

ASMA

1A4

Dako

-

-

-

Myoglobin

polyclonal

Dako

-

-

-

CD34

NU-4A1

Nichirei, Tokyo, Japn

-

-

-

p53 protein

DO-7

Dako

++

++

+

Ki-67

MIB-I

Dako

72%

67%

32%

  1. SCC, squamous cell carcinoma; TCC, transitional cell carcinoma area; +++, 67-100% positive; ++, 33-66%; +, 1-33% positive; -, negative; HMWCK, high molecular weight cytokerain; CK, cytokeratin; EMA, epithelial membrane antigen; ASMA, α-smooth muscle antigen.